Manufactured Anti-BCMA CAR-T cells

Developed for: plasma cell myeloma
Investigated by: Actavis Inc. · Eugia Pharma Specialities Limited · Thomas Martin, MD · University of California, Davis

today NCT05577000 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05577000	Oct 2021 → Nov 2025 overdue	plasma cell myeloma	Thomas Martin, MD	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Manufactured Anti-BCMA CAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577000 ↗
Modality	Cell therapy	“Chimeric antigen receptor T-cell (CAR T) therapy” NCT05577000 ↗